Education and Training
A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of CRG-022, a CD22-directed autologous Chimeric Antigen Receptor (CAR) T-cell therapy for the treatment of relapsed or refractory large B-cell lymphoma (LBCL).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Fludarabine (Conditional therapy)
- drug: Cyclophosphamide Monohydrate (Conditional therapy)
- drug: CRG-022 cells (Experimental drug)
Eligibility
Key Inclusion Criteria:
- Aged ≥18 years
- Relapsed or refractory large B-cell lymphoma.
- For enrollment in cohort 1, patients must have previously received a CD19-directed CAR
T-cell therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate hematological, renal, and liver function
Key Exclusion Criteria:
- Clinically significant concurrent medical illness
- Active infection requiring systemic antibiotics
- Prior allogeneic stem cell transplant or allogeneic cell therapy
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kelly Chyan
650-625-8130
I'm interested